NCT05329025View on ClinicalTrials.gov

A Study of QL1706 Combined With Chemotherapy in Advanced Non-small Cell Lung Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

January 1, 2024

Study Completion Date

January 1, 2024

Conditions
Non-small-cell Lung Cancer
Interventions
DRUG

QL1706

QL1706 will be administered by IV infusion at 5mg/kg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit.

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY